• 1
    Przyklenk K, Kloner RA. Ischemic preconditioning: exploring the paradox. Prog Cardiovasc Dis 1998; 40: 51747.
  • 2
    Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev 2003; 83: 111351.
  • 3
    Hata K, Whittaker P, Kloner RA, Przyklenk K. Brief antecedent ischemia attenuates platelet-mediated thrombosis in damaged and stenotic canine coronary arteries: role of adenosine. Circulation 1998; 97: 692702.
  • 4
    Andreotti F, Pasceri V, Hackett DR, Davies GJ, Haider AW, Maseri A. Preinfarction angina as a predictor of more rapid coronary thrombolysis in patients with acute myocardial infarction. N Engl J Med 1996; 334: 712.
  • 5
    Muller DW, Topol EJ, Califf RM, Sigmon KN, Gorman L, George BS, Kereiakes DJ, Lee KL, Ellis SG. Relationship between antecedent angina pectoris and short-term prognosis after thrombolytic therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. Am Heart J 1990; 119: 22431.
  • 6
    Przyklenk K, Whittaker P. Brief antecedent ischemia enhances recombinant tissue plasminogen activator-induced coronary thrombolysis by adenosine-mediated mechanism. Circulation 2000; 102: 8895.
  • 7
    Folts JD, Crowell Jr EB, Rowe GG. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 1976; 54: 36570.
  • 8
    Folts J. An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. Circulation 1991; 83: IV314.
  • 9
    Ikeda H, Koga Y, Kuwano K, Nakayama H, Ueno T, Yoshida N, Adachi K, Park IS, Toshima H. Cyclic flow variations in a conscious dog model of coronary artery stenosis and endothelial injury correlate with acute ischemic heart disease syndromes in humans. J Am Coll Cardiol 1993; 21: 100817.
  • 10
    Eichhorn EJ, Grayburn PA, Willard JE, Anderson HV, Bedotto JB, Carry M, Kahn JK, Willerson JT. Spontaneous alterations in coronary blood flow velocity before and after coronary angioplasty in patients with severe angina. J Am Coll Cardiol 1991; 17: 4352.
  • 11
    Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications. Circulation 1989; 80: 198205.
  • 12
    Przyklenk K, Hata K, Whittaker P, Elliott GT. Monophosphoryl lipid A: a novel nitric oxide-mediated therapy to attenuate platelet thrombosis? J Cardiovasc Pharmacol 2000; 35: 36675.
  • 13
    Hata K, Whittaker P, Kloner RA, Przyklenk K. Brief myocardial ischemia attenuates platelet thrombosis in remote, damaged, and stenotic carotid arteries. Circulation 1999; 100: 8438.
  • 14
    Przyklenk K, Kloner RA. Sildenafil citrate (Viagra) does not exacerbate myocardial ischemia in canine models of coronary artery stenosis. J Am Coll Cardiol 2001; 37: 28692.
  • 15
    Linden MD, Frelinger III AL, Barnard MR, Przyklenk K, Furman MI, Michelson AD. Application of flow cytometry to platelet disorders. Semin Thromb Hemost 2004; 30: 50111.
  • 16
    Weiss DJ. Flow cytometric evaluation of hemophagocytic disorders in canine. Vet Clin Pathol 2002; 31: 3641.
  • 17
    Moritz A, Walcheck BK, Deye J, Weiss DJ. Effects of short-term racing activity on platelet and neutrophil activation in dogs. Am J Vet Res 2003; 64: 8559.
  • 18
    Barnard MR, Krueger LA, Frelinger III AL, Furman MI, Michelson AD. Whole blood analysis of leukocyte-platelet aggregates. In: RobinsonJP, DarzynkiewiczZ, DeanPN, HibbsAR, OrfaoA, RabinovitchPS, eds. Current Protocols in Cytometry. New York: John Wiley & Sons, 2003:
  • 19
    Krueger LA, Barnard MR, Frelinger III AL, Furman MI, Michelson AD. Immunophenotypic analysis of platelets. In: RobinsonJP, DarzynkiewiczZ, DeanPN, HibbsAR, OrfaoA, RabinovitchPS, eds. Current Protocols in Cytometry. New York: John Wiley & Sons, 2003:
  • 20
    Newman PJ, Berndt MC, Gorski J, White GC II, Lyman S, Paddock C, Muller WA. PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. Science 1990; 247: 121922.
  • 21
    Kenny D, Morateck PA, Fahs SA, Warltier DC, Montgomery RR. Cloning and expression of canine glycoprotein Ibalpha. Thromb Haemost 1999; 82: 132733.
  • 22
    Zoldhelyi P, Beck PJ, Bjercke RJ, Ober JC, Hu X, McNatt JM, Akhtar S, Ahmed M, Clubb Jr FJ, Chen Z-Q, Dixon RAF, Yeh ETH, Willerson JT. Inhibition of coronary thrombosis and local inflammation by a noncarbohydrate selectin inhibitor. Am J Physiol 2000; 279: H306575.
  • 23
    Wu D, Vanhoorelbeke K, Cauwenberghs N, Meiring M, Depraetere H, Kotze HF, Deckmyn H. Inhibition of the von Willebrand (VWF)-collagen interaction by an antihuman VWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons. Blood 2002; 99: 36238.
  • 24
    Wu D, Meiring M, Kotze HF, Deckmyn H, Cauwenberghs N. Inhibition of platelet glycoprotein Ib, glycoprotein IIb/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons. Arterioscler Thromb Vasc Biol 2002; 22: 3238.
  • 25
    Kageyama S, Yamamoto H, Nakazawa H, Yoshimoto R. Anti-human vWF monoclonal antibody, AJvW-2 Fab, inhibits repetitive coronary artery thrombosis without bleeding time prolongation in dogs. Thromb Res 2001; 101: 395404.
  • 26
    Ueyama T, Ikeda H, Haramaki N, Kuwano K, Imaizumi T. Effects of monoclonal antibody to P-selectin and analogue of sialyl Lewis X on cyclic flow variations in stenosed and endothelium-injured canine coronary arteries. Circulation 1997; 95: 15549.
  • 27
    Ikeda H, Ueyama T, Murohara T, Yasukawa H, Haramaki N, Eguchi H, Katoh A, Takajo Y, Onitsuka I, Ueno T, Tojo SJ, Imaizumi T. Adhesive interaction between P-selectin and sialyl Lewis(x) plays an important role in recurrent coronary arterial thrombosis in dogs. Arterioscler Thromb Vasc Biol 1999; 19: 108390.
  • 28
    Shattil SJ, Hoxie JA, Cunningham M, Brass LF. Changes in the platelet membrane glycoprotein IIb-IIIa complex during platelet activation. J Biol Chem 1985; 260: 1110714.
  • 29
    Sarma J, Laan CA, Alam S, Jha A, Fox KA, Dransfield I. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 2002; 105: 216671.
  • 30
    Michelson AD. Flow cytometry: a clinical test of platelet function. Blood 1996; 87: 492536.
  • 31
    Michelson AD. Platelet function testing in cardiovascular diseases. Circulation 2004; 110: e48993.
  • 32
    Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman MI. Circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin: studies in baboons, human coronary intervention, and human acute myocardial infarction. Circulation 2001; 104: 15337.
  • 33
    Rinder HM, Bonan JL, Rinder CS, Ault KA, Smith BR. Activated and unactivated platelet adhesion to monocytes and neutrophils. Blood 1991; 78: 17609.
  • 34
    Wollner A, Wollner S, Smith JB. Acting via A2 receptors, adenosine inhibits the upregulation of Mac-1 (Cd11b/CD18) expression on FMLP-stimulated neutrophils. Am J Respir Cell Mol Biol 1993; 9: 17985.
  • 35
    Thiel M, Chambers JD, Chouker A, Fischer S, Zourelidis C, Bardenheuer HJ, Arfors KE, Peter K. Effect of adenosine on the expression of beta(2) integrins and L-selectin of human polymorphonuclear leukocytes in vitro. J Leukoc Biol 1996; 59: 67182.
  • 36
    Vinten-Johansen J, Thourani VH, Ronson RS, Jordan JE, Zhao ZQ, Nakamura M, Velez D, Guyton RA. Broad-spectrum cardioprotection with adenosine. Ann Thorac Surg 1999; 68: 19428.
  • 37
    Bauer B, Simkhovich BZ, Kloner RA, Przyklenk K. Does preconditioning protect the coronary vasculature from subsequent ischemia/reperfusion injury? Circulation 1993; 88: 65972.
  • 38
    Przyklenk K. Nicotine exacerbates postischemic contractile dysfunction of ‘stunned’ myocardium in the canine model. Possible role of free radicals. Circulation 1994; 89: 127281.
  • 39
    Ovize M, Kloner RA, Hale SL, Przyklenk K. Coronary cyclic flow variations ‘precondition’ ischemic myocardium. Circulation 1992; 85: 77989.
  • 40
    Folts JD, Rowe GG. Epinephrine potentiation of in vivo stimuli reverses aspirin inhibition of platelet thrombus formation in stenosed canine coronary arteries. Thromb Res 1988; 50: 50716.
  • 41
    Hjemdahl P, Larsson PT, Wallen NH. Effects of stress and beta-blockade on platelet function. Circulation 1991; 84: VI4461.
  • 42
    Gryglewski RJ, Szczeklik A, Bieron K. Morphine antagonises prostaglandin E1- mediated inhibition of human platelet aggregation. Nature 1975; 256: 567.
  • 43
    Hsiao G, Shen MY, Fang CL, Chou DS, Lin CH, Chen TF, Sheu JR. Morphine-potentiated platelet aggregation in in vitro and platelet plug formation in in vivo experiments. J Biomed Sci 2003; 10: 292301.
  • 44
    Reches A, Eldor A, Vogel Z, Salomon Y. Do human platelets have opiate receptors? Nature 1980; 288: 3823.
  • 45
    Bertha BG, Folts JD. Inhibition of epinephrine-exacerbated coronary thrombus formation by prostacyclin in the dog. J Lab Clin Med 1984; 103: 20414.
  • 46
    Machleidt C, Rose P, Mittmann U. Prevention of coronary platelet aggregation with a phosphodiesterase inhibitor RX-RA 69. Thromb Res 1985; 37: 595604.
  • 47
    Folts JD, Stamler J, Loscalzo J. Intravenous nitroglycerin infusion inhibits cyclic blood flow responses caused by periodic platelet thrombus formation in stenosed canine coronary arteries. Circulation 1991; 83: 21227.
  • 48
    Yao SK, Ober JC, Krishnaswami A, Ferguson JJ, Anderson HV, Golino P, Buja LM, Willerson JT. Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-injured arteries. Circulation 1992; 86: 13029.
  • 49
    Brune B, Hanstein K. Rapid reversibility of nitric oxide induced platelet inhibition. Thromb Res 1998; 90: 8391.
  • 50
    Bullough DA, Zhang C, Montag A, Mullane KM, Young MA. Adenosine-mediated inhibition of platelet aggregation by acadesine. A novel antithrombotic mechanism in vitro and in vivo. J Clin Invest 1994; 94: 152432.
  • 51
    Kitakaze M, Hori M, Sato H, Takashima S, Inoue M, Kitabatake A, Kamada T. Endogenous adenosine inhibits platelet aggregation during myocardial ischemia in dogs. Circ Res 1991; 69: 14028.
  • 52
    Minamino T, Kitakaze M, Asanuma H, Tomiyama Y, Shiraga M, Sato H, Ueda Y, Funaya H, Kuzuya T, Matsuzawa Y, Hori M. Endogenous adenosine inhibits P-selectin-dependent formation of coronary thromboemboli during hypoperfusion in dogs. J Clin Invest 1998; 101: 164353.
  • 53
    Sandoli D, Chiu PJ, Chintala M, Dionisotti S, Ongini E. In vivo and ex vivo effects of adenosine A1 and A2 receptor agonists on platelet aggregation in the rabbit. Eur J Pharmacol 1994; 259: 439.
  • 54
    Linden MD, Michelson AD, Barnard MR, Frelinger III AL, Furman MI, Przyklenk K. Does adenosine A2 receptor stimulation trigger the favorable ‘anti-platelet’ effect of preconditioning ischemia? Arterioscler Thromb Vasc Biol 2006; 25: e-46.
  • 55
    Linden MD, Michelson AD, Barnard MR, Frelinger III AL, Furman MI, Przyklenk K. In vitro adenosine A2 receptor stimulation inhibits platelet activation in humans. Arterioscler Thromb Vasc Biol 2006; 26: e-58 (abstract).
  • 56
    Harrison GJ, Willis RJ, Headrick JP. Extracellular adenosine levels and cellular energy metabolism in ischemically preconditioned rat heart. Cardiovasc Res 1998; 40: 7487.